Skip to content

Multiparametric Cardio-hepatic MRI in Patients With Noncirrhotic Portal Hypertension

Multiparametric Cardio-hepatic MRI in Patients With Noncirrhotic Portal Hypertension

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05041452
Enrollment
60
Registered
2021-09-13
Start date
2021-04-29
Completion date
2023-12-31
Last updated
2021-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Portal, Cardiomyopathies

Keywords

Cardiac MRI, Hepatic MRI

Brief summary

The aim of this study is to use multiparametric MRI to investigate any differences in myocardial structure and function in patients with noncirrhotic portal hypertension compared with a control group with liver cirrhosis.

Detailed description

The term cirrhotic cardiomyopathy (CCM) was defined in 2005 according to expert consensus at the World Congress of Gastroenterology in Montreal as a clinical phenotype in patients with liver cirrhosis consisting of systolic and diastolic dysfunction and a complementary criterion, such as electrophysiological changes, without the presence of a known underlying cardiac disease. For a long time, CCM was considered to result from toxic effects of alcohol consumption. The current view is that CCM is a separate entity independent of the various etiologies of liver cirrhosis. Thus, generally impaired liver function and portal hypertension with splanchnic vasodilation leads to altered hemodynamic conditions with central hypovolemia, increased activation of volume and baroreceptors, especially of the sympathetic nervous system, resulting in a hyperdynamic syndrome with increased cardiac stress. However, the contribution of portal hypertension to CCM is unclear. With new MRI techniques such as cardiac T1 and T2 mapping and extracellular volume fraction (ECV), quantitative parameters are available to detect pathologies of the myocardium before they become detectable with conventional techniques in cardiac MRI or echocardiography. The aim of this study is to use multiparametric MRI to investigate any differences in myocardial structure and function in patients with noncirrhotic portal hypertension compared with a control group with liver cirrhosis and to investigate a quantifiable correlation between cardiac, hepatic, and splenic parameters.

Interventions

Multiparametric cardiac magnetic resonance, including functional and structural parameters

Sponsors

University Hospital, Bonn
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years

Inclusion criteria

1. noncirrhotic portal hypertension 2. age at least 18 years

Exclusion criteria

1. underlying cardiac disease, e.g., coronary heart disease/myocardial infarction, myocarditis, cardiomyopathies of other causes, congenital heart disease 2. patients who are using a intrauterinpessare for contraception 3. pregnant and breastfeeding women 4. patients with contraindications for MRI (not suitebale metallic implants) 5. patients with contraindications for MRI contrast agents (renal insufficiency, allergy)

Design outcomes

Primary

MeasureTime frameDescription
Myocardial T1 relaxation timeMeasurement will be performed within 2 weeks after MRI scan.T1 relaxation times will be obtained to asses acute myocardial injury and fibrosis. T1 maps will be analyzed using a segmental approach by region of interest analysis. T1 relaxation times are given in \[ms\].

Secondary

MeasureTime frameDescription
Myocardial T2 relaxation timeMeasurement will be performed within 2 weeks after MRI scan.T2 relaxation times will be obtained to asses myocardial edema. T2 maps will be analyzed using a segmental approach by region of interest analysis. T2 relaxation times are given in \[ms\].
Myocardial ECVMeasurement will be performed within 2 weeks after MRI scan.Myocardial extracellular volume will be obtained to asses extracellular space/myocardial fibrosis. ECV values will be calculated using a segmental approach by region of interest analysis of native and contrast-enhanced T1 relaxation maps. ECV values are given in \[%\].
Myocardial strainMeasurement will be performed within 2 weeks after MRI scan.Cardiac magnetic resonance feature-tracking will be used to asses left ventricular longitudinal, circumferential and radial strain.

Countries

Germany

Contacts

Primary ContactJulian A Luetkens, PD Dr. med.
julian.luetkens@ukbonn.de+49 228 287-15960
Backup ContactAlexander Isaak, Dr. med.
alexander.isaak@ukbonn.de+49 228 287-15960

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026